Last update 08 May 2025

CLDN18.2 x Top II

Basic Info

Related Targets
CLDN18.2Top II

Related

1
Drugs associated with CLDN18.2 x Top II
SOT-102
Target
CLDN18.2 x Top II
Mechanism
CLDN18.2 inhibitors [+1]
Active Org.-
Originator Org.
Excoso asExcoso as
Active Indication-
Inactive Indication
Advanced Pancreatic Adenocarcinoma [+4]
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with CLDN18.2 x Top II
NCT05525286
/ TerminatedPhase 1/2
A Multicentric Phase 1/2 Trial to Evaluate the Safety and Efficacy of SOT102 as Monotherapy and in Combination With Standard of Care Treatment in Patients With Gastric and Pancreatic Adenocarcinoma
100 Clinical Results associated with CLDN18.2 x Top II
Login to view more data
100 Translational Medicine associated with CLDN18.2 x Top II
Login to view more data
0 Patents (Medical) associated with CLDN18.2 x Top II
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free